Post by Solitek Pharma

A solid form is not controlled because we named it in a specification. It is controlled because the process consistently produces it, preserves it, and detects meaningful changes before they affect product quality. That is where Quality by Design becomes very practical. For solid-state development, QbD is not a slogan and it is not a regulatory fashion. It is the discipline of understanding which material attributes and process parameters can change the API form, particle properties, stability, and performance, then designing a control strategy around that understanding. The final crystallization step is often where the physical identity of the drug substance is created. Solvent composition, supersaturation profile, seeding, cooling rate, antisolvent addition, impurity profile, water activity, filtration, washing, drying, milling, micronization, and storage can all influence the resulting form or its transformation risk. Some variables affect chemical purity; others affect physical quality. Both matter, but they are not controlled in the same way. A common weakness is to treat form control as an end-product test. XRPD confirms the desired form, so the batch passes. But end-product testing alone does not explain why the right form appeared, whether the process is close to a transformation boundary, or what will happen when the process is scaled, transferred, or exposed to normal variability. By the time the wrong form is detected at release, the batch has already absorbed the cost of failure. A stronger QbD approach links the desired solid form to the process design. It identifies the critical material attributes and critical process parameters that influence form outcome. It evaluates where transformations could occur. It uses development studies to define an operating space. It builds appropriate in-process controls, analytical methods, and stability monitoring. It also avoids over-controlling attributes that are not clinically or operationally relevant. ICH Q8, Q9, and Q11 all point in this direction: product and process understanding, risk-based development, and a control strategy capable of consistently delivering intended quality. For solid forms, this means understanding not only what form you want, but how your process makes it and keeps it. At Solitek Pharma, we see QbD as the point where solid-state science becomes manufacturing confidence. The goal is not to make development slower. The goal is to prevent late-stage surprises from becoming process deviations, rejected batches, regulatory questions, or supply risk. The molecule will experience the manufacturing process whether we understand it or not. QbD is how we make sure that experience is predictable. Where do you see the biggest gap in form control: crystallization, drying, milling, tech transfer, or specifications? #QbD #process #manufacturing #quality